Cargando…

Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers

BACKGROUND: Utilization of chemotherapy for patients with muscle-invasive bladder cancer (MIBC) is low. In earlier qualitative work we used the Theoretical Domains Framework (TDF) to determine barriers and enablers of chemotherapy use. In this project we aimed to determine the prevalence of these ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Melanie, Doiron, R. Christopher, French, Simon D., Brennan, Kelly, Feldman-Stewart, Deb, Siemens, D. Robert, Mackillop, William J., Booth, Christopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798532/
https://www.ncbi.nlm.nih.gov/pubmed/29430507
http://dx.doi.org/10.3233/BLC-170148
_version_ 1783297856949452800
author Walker, Melanie
Doiron, R. Christopher
French, Simon D.
Brennan, Kelly
Feldman-Stewart, Deb
Siemens, D. Robert
Mackillop, William J.
Booth, Christopher M.
author_facet Walker, Melanie
Doiron, R. Christopher
French, Simon D.
Brennan, Kelly
Feldman-Stewart, Deb
Siemens, D. Robert
Mackillop, William J.
Booth, Christopher M.
author_sort Walker, Melanie
collection PubMed
description BACKGROUND: Utilization of chemotherapy for patients with muscle-invasive bladder cancer (MIBC) is low. In earlier qualitative work we used the Theoretical Domains Framework (TDF) to determine barriers and enablers of chemotherapy use. In this project we aimed to determine the prevalence of these barriers and enablers in Canadian physicians. METHODS: Practicing Canadian urologists, medical oncologists (MOs) and radiation oncologists (ROs) participated in a specialty-specific web-based quantitative survey to assess potential barriers and enablers to chemotherapy use. Survey questions were developed that were thematically mapped to TDF domains. Logistic regression was used to identify TDF domains associated with high referral/use of chemotherapy. RESULTS: 110 urologists, 47 MOs and 43 ROs completed the survey; response rates were 20%, 35% and 31% respectively. The mean reported survival gain associated with neoadjuvant chemotherapy (NACT) was 9%, 8%, and 7% for urologists, MOs, and ROs respectively. Among participating urologists, the TDF domains ‘social and professional role’ (OR = 16.5, 95% CI 4.6–59.2), ‘social influences’ (OR = 5.7, 95% CI 2.4–13.4) ‘beliefs about consequences’ (OR = 4.9, 95% CI 1.8–13.3) and ‘memory, attention and decision-making’ (OR = 0.50, 95% CI 0.27–0.91) were associated with MO referral rates. Among MOs, the TDF domains ‘behavioural regulation’, ‘social influences’, and ‘social and professional role’ were associated with greater use of chemotherapy (p < 0.05). No TDF domains were associated with RO referral to MO. CONCLUSIONS: We have identified several factors associated with referral/use of chemotherapy for MIBC. Optimization of multidisciplinary patient care needs to be considered when designing future interventions to close the gap between evidence and practice.
format Online
Article
Text
id pubmed-5798532
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-57985322018-02-08 Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers Walker, Melanie Doiron, R. Christopher French, Simon D. Brennan, Kelly Feldman-Stewart, Deb Siemens, D. Robert Mackillop, William J. Booth, Christopher M. Bladder Cancer Research Report BACKGROUND: Utilization of chemotherapy for patients with muscle-invasive bladder cancer (MIBC) is low. In earlier qualitative work we used the Theoretical Domains Framework (TDF) to determine barriers and enablers of chemotherapy use. In this project we aimed to determine the prevalence of these barriers and enablers in Canadian physicians. METHODS: Practicing Canadian urologists, medical oncologists (MOs) and radiation oncologists (ROs) participated in a specialty-specific web-based quantitative survey to assess potential barriers and enablers to chemotherapy use. Survey questions were developed that were thematically mapped to TDF domains. Logistic regression was used to identify TDF domains associated with high referral/use of chemotherapy. RESULTS: 110 urologists, 47 MOs and 43 ROs completed the survey; response rates were 20%, 35% and 31% respectively. The mean reported survival gain associated with neoadjuvant chemotherapy (NACT) was 9%, 8%, and 7% for urologists, MOs, and ROs respectively. Among participating urologists, the TDF domains ‘social and professional role’ (OR = 16.5, 95% CI 4.6–59.2), ‘social influences’ (OR = 5.7, 95% CI 2.4–13.4) ‘beliefs about consequences’ (OR = 4.9, 95% CI 1.8–13.3) and ‘memory, attention and decision-making’ (OR = 0.50, 95% CI 0.27–0.91) were associated with MO referral rates. Among MOs, the TDF domains ‘behavioural regulation’, ‘social influences’, and ‘social and professional role’ were associated with greater use of chemotherapy (p < 0.05). No TDF domains were associated with RO referral to MO. CONCLUSIONS: We have identified several factors associated with referral/use of chemotherapy for MIBC. Optimization of multidisciplinary patient care needs to be considered when designing future interventions to close the gap between evidence and practice. IOS Press 2018-01-20 /pmc/articles/PMC5798532/ /pubmed/29430507 http://dx.doi.org/10.3233/BLC-170148 Text en © 2018 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Report
Walker, Melanie
Doiron, R. Christopher
French, Simon D.
Brennan, Kelly
Feldman-Stewart, Deb
Siemens, D. Robert
Mackillop, William J.
Booth, Christopher M.
Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers
title Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers
title_full Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers
title_fullStr Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers
title_full_unstemmed Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers
title_short Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers
title_sort peri-operative chemotherapy for bladder cancer: a survey of providers to determine barriers and enablers
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798532/
https://www.ncbi.nlm.nih.gov/pubmed/29430507
http://dx.doi.org/10.3233/BLC-170148
work_keys_str_mv AT walkermelanie perioperativechemotherapyforbladdercancerasurveyofproviderstodeterminebarriersandenablers
AT doironrchristopher perioperativechemotherapyforbladdercancerasurveyofproviderstodeterminebarriersandenablers
AT frenchsimond perioperativechemotherapyforbladdercancerasurveyofproviderstodeterminebarriersandenablers
AT brennankelly perioperativechemotherapyforbladdercancerasurveyofproviderstodeterminebarriersandenablers
AT feldmanstewartdeb perioperativechemotherapyforbladdercancerasurveyofproviderstodeterminebarriersandenablers
AT siemensdrobert perioperativechemotherapyforbladdercancerasurveyofproviderstodeterminebarriersandenablers
AT mackillopwilliamj perioperativechemotherapyforbladdercancerasurveyofproviderstodeterminebarriersandenablers
AT boothchristopherm perioperativechemotherapyforbladdercancerasurveyofproviderstodeterminebarriersandenablers